论文部分内容阅读
目的 探讨胃癌雌激素受体 (ER)实际表达率 ,为临床使用新一代抗ER药物 (toremifene ,TOR)治疗胃癌提供临床病理依据。方法 用免疫组化法对 349例胃癌标本进行ER的检测 ,其中 2 99例用ABC(avidinbiotinperoxidasecomplex)法 ,5 0例用葡聚糖聚合物技术二步法进行检测。在检测ER的同时也检测 p5 3及PCNA的表达。结果 两种检测方法的ER阳性率分别为 2 .3% (7/ 2 99)及 0 % (0 / 5 0 ) ,p5 3阳性率 37.1% (111/ 2 99)及 4 6 %(2 3/ 5 0 ) ,PCNA 94 .3% (2 82 / 2 99)及 96 % (48/ 5 0 )。结论 胃癌细胞可表达ER但实际表达率很低 ,而且存在质和量的变化。tamoxifen (TAM )及TOR的抗胃癌效应需要进一步研究
Objective To investigate the actual expression rate of estrogen receptor (ER) in gastric cancer and to provide a clinicopathological evidence for the clinical use of a new generation of anti-ER drug (TOR) in the treatment of gastric cancer. Methods 349 samples of gastric cancer were detected by immunohistochemical method. Among them, 2 99 cases were detected by avidin biotin peroxidase complex (ABC) and 50 cases by dextran polymer technique. The expression of p5 3 and PCNA was also examined at the same time of detecting ER. Results The positive rates of ER in the two methods were 2.3% (7/99) and 0% (0/50), respectively. The positive rate of p5 3 was 37.1% (111/299) and 46% (23% / 50), PCNA 94.3% (2 82/299), and 96% (48/50). Conclusion The gastric cancer cells can express ER, but the actual expression rate is very low, and there are changes in the quality and quantity. Anti-gastric cancer effects of tamoxifen (TAM) and TOR require further study